Satellite Epidemic of Covid-19 Associated Mucormycosis in India : A Multi-Site Observational Study
© 2023. The Author(s), under exclusive licence to Springer Nature B.V..
BACKGROUND: Sudden upsurge in cases of COVID-19 Associated Mucormycosis (CAM) following the second wave of the COVID-19 pandemic was recorded in India. This study describes the clinical characteristics, management and outcomes of CAM cases, and factors associated with mortality.
METHODS: Microbiologically confirmed CAM cases were enrolled from April 2021 to September 2021 from ten diverse geographical locations in India. Data were collected using a structured questionnaire and entered into a web portal designed specifically for this investigation. Bivariate analyses and logistic regression were conducted using R version 4.0.2.
RESULTS: A total of 336 CAM patients were enrolled; the majority were male (n = 232, 69.1%), literate (n = 261, 77.7%), and employed (n = 224, 66.7%). The commonest presenting symptoms in our cohort of patients were oro-facial and ophthalmological in nature. The median (Interquartile Range; IQR) interval between COVID diagnosis and admission due to mucormycosis was 31 (18, 47) days, whereas the median duration of symptoms of CAM before hospitalization was 10 (5, 20) days. All CAM cases received antifungal treatment, and debridement (either surgical or endoscopic or both) was carried out in the majority of them (326, 97.02%). Twenty-three (6.9%) of the enrolled CAM cases expired. The odds of death in CAM patients increased with an increase in HbA1c level (aOR: 1.34, 95%CI: 1.05, 1.72) following adjustment for age, gender, education and employment status.
CONCLUSION: A longer vigil of around 4-6 weeks post-COVID-19 diagnosis is suggested for earlier diagnosis of CAM. Better glycemic control may avert mortality in admitted CAM cases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
|---|---|
| Enthalten in: |
Mycopathologia - 188(2023), 5 vom: 25. Okt., Seite 745-753 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Diabetes mellitus |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11046-023-00770-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359904580 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359904580 | ||
| 003 | DE-627 | ||
| 005 | 20231226081854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11046-023-00770-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359904580 | ||
| 035 | |a (NLM)37490256 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Satija, Aanchal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Satellite Epidemic of Covid-19 Associated Mucormycosis in India |b A Multi-Site Observational Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature B.V. | ||
| 520 | |a BACKGROUND: Sudden upsurge in cases of COVID-19 Associated Mucormycosis (CAM) following the second wave of the COVID-19 pandemic was recorded in India. This study describes the clinical characteristics, management and outcomes of CAM cases, and factors associated with mortality | ||
| 520 | |a METHODS: Microbiologically confirmed CAM cases were enrolled from April 2021 to September 2021 from ten diverse geographical locations in India. Data were collected using a structured questionnaire and entered into a web portal designed specifically for this investigation. Bivariate analyses and logistic regression were conducted using R version 4.0.2 | ||
| 520 | |a RESULTS: A total of 336 CAM patients were enrolled; the majority were male (n = 232, 69.1%), literate (n = 261, 77.7%), and employed (n = 224, 66.7%). The commonest presenting symptoms in our cohort of patients were oro-facial and ophthalmological in nature. The median (Interquartile Range; IQR) interval between COVID diagnosis and admission due to mucormycosis was 31 (18, 47) days, whereas the median duration of symptoms of CAM before hospitalization was 10 (5, 20) days. All CAM cases received antifungal treatment, and debridement (either surgical or endoscopic or both) was carried out in the majority of them (326, 97.02%). Twenty-three (6.9%) of the enrolled CAM cases expired. The odds of death in CAM patients increased with an increase in HbA1c level (aOR: 1.34, 95%CI: 1.05, 1.72) following adjustment for age, gender, education and employment status | ||
| 520 | |a CONCLUSION: A longer vigil of around 4-6 weeks post-COVID-19 diagnosis is suggested for earlier diagnosis of CAM. Better glycemic control may avert mortality in admitted CAM cases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Fungal infection | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Pandemic | |
| 650 | 4 | |a SARS-CoV 2 | |
| 650 | 4 | |a Second wave | |
| 700 | 1 | |a Anand, Tanu |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Aparna |e verfasserin |4 aut | |
| 700 | 1 | |a Velamuri, Poonam Sharma |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Kh Jitenkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Madhuchhanda |e verfasserin |4 aut | |
| 700 | 1 | |a Josten, Kripa |e verfasserin |4 aut | |
| 700 | 1 | |a Keche, Archana Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nagarkar, Nitin M |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Himanshu, D |e verfasserin |4 aut | |
| 700 | 1 | |a Mistry, Sejal N |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Jimy D |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Prajwal |e verfasserin |4 aut | |
| 700 | 1 | |a Rohatgi, Shalesh |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Soumitra |e verfasserin |4 aut | |
| 700 | 1 | |a Hazra, Avijit |e verfasserin |4 aut | |
| 700 | 1 | |a Kindo, Anupma Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Annamalai, Radha |e verfasserin |4 aut | |
| 700 | 1 | |a Rudramurthy, Shivaprakash M |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Mini P |e verfasserin |4 aut | |
| 700 | 1 | |a Shameem, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Fatima, Nazish |e verfasserin |4 aut | |
| 700 | 1 | |a Khambholja, Janakkumar R |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sangita |e verfasserin |4 aut | |
| 700 | 1 | |a Madkaikar, Manisha |e verfasserin |4 aut | |
| 700 | 1 | |a Pradhan, Vandana D |e verfasserin |4 aut | |
| 700 | 1 | |a Bhargava, Anudita |e verfasserin |4 aut | |
| 700 | 1 | |a Mehata, Rupa |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Ripu Daman |e verfasserin |4 aut | |
| 700 | 1 | |a Tigga, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Banerjee, Gopa |e verfasserin |4 aut | |
| 700 | 1 | |a Sonkar, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Malhotra, Hardeep Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Neeraj |e verfasserin |4 aut | |
| 700 | 1 | |a Patil, Rajashri |e verfasserin |4 aut | |
| 700 | 1 | |a Raut, Chandrashekhar G |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharyya, Kumkum |e verfasserin |4 aut | |
| 700 | 1 | |a Arthur, Preetam |e verfasserin |4 aut | |
| 700 | 1 | |a Somu, L |e verfasserin |4 aut | |
| 700 | 1 | |a Srikanth, Padma |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Pankaj B |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Naresh K |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Dipti |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Wasil |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Aftab |e verfasserin |4 aut | |
| 700 | 1 | |a Bathla, Meeta |e verfasserin |4 aut | |
| 700 | 1 | |a Solanki, Sunita |e verfasserin |4 aut | |
| 700 | 1 | |a Doshi, Hiren |e verfasserin |4 aut | |
| 700 | 1 | |a Kanani, Yash |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Nishi |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Zincal |e verfasserin |4 aut | |
| 700 | 1 | |a Tembhurne, Alok Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Rajguru, Chhaya |e verfasserin |4 aut | |
| 700 | 1 | |a Sankhe, Lalitkumar R |e verfasserin |4 aut | |
| 700 | 1 | |a Chavan, Shrinivas S |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Reetika Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Panda, Samiran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycopathologia |d 1975 |g 188(2023), 5 vom: 25. Okt., Seite 745-753 |w (DE-627)NLM000021288 |x 1573-0832 |7 nnns |
| 773 | 1 | 8 | |g volume:188 |g year:2023 |g number:5 |g day:25 |g month:10 |g pages:745-753 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11046-023-00770-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2023 |e 5 |b 25 |c 10 |h 745-753 | ||